lebrikizumab (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

Atopic Dermatitis

Pending FDA approval for moderate-to-severe atopic dermatitis

Next:

Pharmacology

Mechanism of Action

Monoclonal antibody that binds to interleukin-13 (IL-13), thereby inhibiting cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and IgE

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.